When administered by subcutaneous (s.c) injection, ERO1α-competent tumors developed readily within just 2 weeks of cell transfer, whereas ERO1α-deficient cancer cells failed to drive tumor formation in recipient animals (n = 6 per group). The gene discussed is ERO1A; the disease is cancer.